BGNE - ベイジ―ン (BeiGene Ltd.) ベイジ―ン



symbol BGNE
会社名 BeiGene Ltd (ベイジ―ン)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ベイジーン(BeiGene Ltd.)は主にバイオ医薬品事業に従事する中国を拠点とする企業である。同社は主に、がんの治療用の革新的分子標的薬および免疫腫瘍薬の研究開発、製造および販売に従事する。同社の主要製品には、ザヌブチニブ(BGB-3111)、チーズリズマブ(BGB-A317)、パミパリブ(BGB-290)がある。   ベイジ―ンはケイマン諸島籍のバイオ医薬品企業。臨床ステ―ジで、主にがん免疫療法の開発に従事。分子標的の抗がん剤候補薬には、BTK(ブルトン型チロシンキナ―ゼ)阻害薬であるRAFタンパク質複合体と、PARP(ポリADPポリキナ―ゼ)阻害薬などを含む。オ―ストラリアとニュ―ジ―ランドで臨床実験を行い、ニュ―ジャ―ジ―州や北京などにオフィスを構える。   
本社所在地 c/o Mourant Ozannes Corporate Services (Cayman) Limited 94 Solaris Avenue Camana Bay Grand Cayman KY1-1108 CYM
代表者氏名 John V Oyler ジョンVオイラー
代表者役職名 Chairman of the Board Chief Executive Officer Founder
電話番号 +1 345-949-4123
設立年月日 40452
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 900人
adr_tso 37297255
EBITDA EBITDA(百万ドル) -254.81800
終値(lastsale) 146.44
時価総額(marketcap) 5461810022.2
時価総額 時価総額(百万ドル) 17144.82
売上高 売上高(百万ドル) 323.73500
企業価値(EV) 企業価値(EV)(百万ドル) 15984.943
当期純利益 当期純利益(百万ドル) -240.77800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Beigene Ltd (ADR) revenues increased from $0K to $85.3M. Net loss increased from $111.2M to $261.5M. Revenues reflect Collaboration revenue increase from $0K to $30.7M. Higher net loss reflects Research and development - Balancing increase from $80.7M to $251.2M (expense) General and administrative - Balancing increase from $15.8M to $60.8M (expense).



   BeiGene in pact with InnoRNA to develop messenger RNA-based therapies  2022/07/06 11:37:24 Seeking Alpha
Chinese biotechnology company, BeiGene (BGNE) announced on Wednesday an agreement to develop messenger RNA-based therapies in partnership with InnoRNA, a biotech with expertise in…
   BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies  2022/07/06 11:00:00 Business Wire
BeiGene announced it entered into a worldwide strategic collaboration with InnoRNA to develop mRNA-based therapeutics.
   Novartis, BeiGene tislelizumab improves survival of esophageal cancer patients in trial  2022/06/30 10:54:31 Seeking Alpha
Novartis (NVS) and BeiGene (BGNE) said tislelizumab plus chemotherapy helped improve overall ((OS)) survival in certain patients with esophageal cancer in a late-stage study.Data from…
   New Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapy  2022/06/30 08:00:00 GlobeNewswire
Basel, June 30, 2022 — Today Novartis announced results from the Phase III RATIONALE 306 trial showing tislelizumab plus chemotherapy significantly improved overall survival (OS) as a first-line treatment for adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC), regardless of PD-L1 status. Tislelizumab plus chemotherapy demonstrated a median OS of 17.2 months (CI, 15.8-20.1 months) versus 10.6 months (CI, 9.3-12.1 months) in patients receiving chemotherapy plus placebo and reduced the risk of death by 34% (hazard ratio=0.66; CI, 0.54-0.80, p<0.0001). 1 In collaboration with BeiGene, these data were presented today during a late-breaking oral session at the 2022 European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer (Abstract #LBA-1).
   Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma  2022/06/27 00:30:00 PR Newswire Asia (English)
- Selinexor is an oral small molecule XPO1 inhibitor ; tislelizumab is an anti-PD-1 checkpoint inhibitor SHANGHAI and HONG KONG , June 27, 2022 /PRNewswire/ -- Antengene Corporation Limited ( "Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has entered into a clinical trial collaboration with BeiGene to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of selinexor in combination with BeiGene''s anti-PD-1 checkpoint inhibitor, tislelizumab. This multi-center, open-label Phase I/II trial will evaluate the investigational combination as a potential treatment option for patients with T and NK-cell lymphoma . "We are delighted to partner with BeiGene, a company that strives for innovation and excellence, and is committed to developing best-in-class or first-in-class anti-cancer therapies for patients across the globe.
   BeiGene GAAP EPADS of -$4.24 beats by $1.08, revenue of $306.63M beats by $6.22M  2022/05/05 12:41:57 Seeking Alpha
BeiGene press release (BGNE): Q1 GAAP EPADS of -$4.24 beats by $1.08.Revenue of $306.63M (-49.4% Y/Y) beats by $6.22M.
   BeiGene Reports First Quarter 2022 Financial Results  2022/05/05 11:00:00 Business Wire
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported financial results for the first quarter of 2022, recent business highlights, and anticipated upcoming milestones. “I have never been more confident in BeiGene. We made terrific progress in the first quarter with our global commercial performance in the U.S.
   Amgen, BeiGene''s Blincyto gets conditional approval in China to treat blood cancer subtype in children  2022/05/04 10:30:30 Seeking Alpha
China''s National Medical Products Administration ((NMPA)) granted conditional approval to BeiGene (BGNE) and Amgen''s (AMGN) Blincyto injection to treat children with relapsed or…
   BeiGene Announces the Approval in China of BLINCYTO (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)  2022/05/04 09:53:00 Wallstreet:Online
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the China National Medical Products Administration (NMPA) has granted conditional approval of BLINCYTO (blinatumomab) for injection for the treatment of pediatric
   BeiGene stock rises 10% as biotech breaks ground at new manufacturing site in New Jersey  2022/04/29 13:50:22 Seeking Alpha
Beijing-based BeiGene (BGNE) announced the groundbreaking of its flagship U.S
   BeiGene: Q4 Earnings Insights  2022/02/25 13:41:04 Benzinga
BeiGene (NASDAQ: BGNE ) reported its Q4 earnings results on Friday, February 25, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings BeiGene missed estimated earnings by 19.15%, reporting an EPS … Full story available on
   BeiGene GAAP EPADS of -$6.16 misses by $1.29, revenue of $214M beats by $0.64M  2022/02/25 12:18:18 Seeking Alpha
BeiGene press release (BGNE): Q4 GAAP EPADS of -$6.16 misses by $1.29.Revenue of $214M (+113.8% Y/Y) beats by $0.64M.Cash, Cash Equivalents, Restricted Cash and Short-Term…
   BeiGene Reports Fourth Quarter and Full Year 2021 Financial Results  2022/02/25 12:00:00 Business Wire
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported financial results for the fourth quarter and full year of 2021, recent business highlights, and anticipated upcoming milestones. “Last year was transformative for our company, and we have built strategic competitive advantages that will help BeiGene to achieve our mission of ma
   BeiGene''s Brukinsa Applications Under FDA, European Review For Leukemia  2022/02/22 17:17:38 Benzinga
The European Medicines Agency (EMA) has accepted for review two new indication applications for BeiGene Ltd''s (NASDAQ: BGNE ) Brukinsa (zanubrutinib) for chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL). In November 2021, Brukinsa received its
   BeiGene''s Brukinsa gets FDA review for expanded use in blood cancer subtype  2022/02/22 14:20:12 Seeking Alpha
The U.S. Food and Drug Administration ((FDA)) accepted BeiGene''s (BGNE) application seeking approval of Brukinsa (zanubrutinib) to treat adult patients with chronic lymphocytic

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ベイジ―ン BGNE BeiGene Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)